Skip to main content

Interview with Sarath Naru of Ventureast

Ventureast, recognized as one of the committed early-stage investors in India, has been investing quite actively in 2008 across three funds – the sector-agnostic “Proactive Fund”, the seed level-focused Ventureast-Tenet Fund and the Biotech Venture Fund. While Proactive Fund and Ventureast-Tenet were raised in 2007, the firm is raising a new successor fund to the biotech fund under the new name of “Life Fund”. Also, in November 2008, the Ventureast-sponsored special purpose acquisition company (SPAC) or "blank check" company announced that it is acquiring an over 80% stake in Solar Semiconductor Ltd., a Hyderabad-based maker of solar photovoltaic modules.



Sarath Naru, Managing Partner of Ventureast, recently spoke to N. Sriram of Venture Intelligence on the new developments at the firm. Some excerpts:

Venture Intelligence: Now that there are a few others firms focusing on the seed-to-early stage funding space, will there be a change in your strategy?

Sarath Naru: We are venture style investors into highly differentiated businesses and unproven risk is the essence of our style of investing. I don’t think we would start doing private equity kind of investments.


VI: Which are the sectors that you would invest in going forward? Which are the sectors that you would stay away from?


SN: We are open to investing in all the businesses where there is innovation and sectors which are rapidly growing. Innovation could be in the business model as opposed to technology innovation.

We don’t do pure play Real Estate. However, we do invest in infrastructure-related services - one of our bigger investments was in Ocean Sparkle. We have recently invested in a company that is into water supply infrastructure and irrigation infrastructure for semi-urban and rural areas.

On the Economic Slowdown

VI: What is the impact of the global economic slowdown on fund raising?

SN: Investors believe that VCs will be least affected by the current situation. We think experienced managers should be able to continue fund raising.

VI: How would the economic slowdown impact valuations?

SN: In India, there has never been abundance of early stage money though there has been early stage investing in the tech side over the last 12-18 months. The valuations were not abnormal. My belief is that this would continue and founders will figure out ways to stretch money longer.

VI: What about deal flow?

SN: I think it is going to get tight. One reason is that some of the funded companies have vanished. Non-cyclical sectors will see decent deal flows. It is because of this reason we feel that healthcare would see a lot of action.

On Life Sciences

VI: How different is investing in life sciences from other sectors?

SN: Investing in drug discovery and device development related companies requires very different skills from IT oriented tech investing. Very little drug discovery and device development kind of work happens in India. A fund manager’s ability to be patient matters a lot. With drug discovery and medical devices, the valuation of the business does not change until much later. Even after reaching phase 3 clinical trial, the success rate still remains 1 in 7. It is a lot more complex than IT investing.

VI: You are now raising a successor fund to your Biotech Fund under the name of Life Fund. What’s behind the name change?

SN: We wanted our earlier fund to be first Biotech Fund in India. Since then, environmental related concerns have become very important. We need clean environment related solutions for sewage, garbage disposals and so on. It is all about improving your life through pharma, healthcare, drug discovery, food and agri-products. Hence the change of name to Life Fund (to capture the broader focus).

VI: We thought Trans-India Acquisition Corp. was originally floated to invest into Life Sciences; but it has ended up investing into a solar tech company. Why?

SN: The mandate of the fund was to invest in Life Sciences or renewable energy segments. Life Science did not happen not because of lack of opportunity but because of valuation concerns. We felt that valuations in the pharmaceuticals/life science space in India were pretty high. Also, we had to list or reverse merge the company with a US-listed company. So it had to have some arbitrage with the multiples in the US. If there was no arbitrage between the Indian and the US multiples, there was no value to the investors in the US. Also, the tax structure and regulations to do the same deal with a listed company were also very complicated.

Popular posts from this blog

PE-VC investments in Q2'23 decline 33% to $9.9 Billion

Private Equity-Venture Capital (PE-VC) investments in India during the quarter ended June 2023 (Q2'23), at $9.85 Billion across 182 deals, registered a 33% decrease compared to the same period in 2022 (which saw $14.6 Billion being invested across 371 deals). The investment amount however rose 74% compared to the immediate previous quarter (which saw $5.7 Billion being invested across 181 deals), shows data from  Venture Intelligence , a research service focused on private company financials, transactions, and their valuations. The PE-VC investment figures for the first 6 months of 2023 - at $15.5 Billion (across 363 deals) - was 50% lower compared to the same period in 2022 (which saw $31 Billion being invested across 800 deals). Q2’23 witnessed 19 mega deals ($100 M+

Chiratae, Speciale and Stride Ventures win APEX'24 Venture Capital Awards

Chiratae Ventures, Speciale Invest and Stride Ventures were awarded as among the leading Venture Capital investors in India for 2023 as part of Venture Intelligence APEX‘24 Private Equity & Venture Capital awards event in Mumbai.  The Venture Intelligence “Awards for Private Equity Excellence” (APEX) is dedicated to celebrating the best that the Indian Private Equity & Venture Capital industry has to offer. The APEX Awardees are selected based on both Self Nomination by the participating PE-VC firms and "crowd sourced" voting from the Limited Partner, PE-VC and advisory communities. (The main criteria are Return Track Record, New Fund Raises & Follow-on Funding Rounds for Portfolio Companies) VC Investor of the Year Chiratae Ventures received the Venture Capital Investor of the Year 2023 Award on the back of 10 part exits totaling $178 million via Secondary Sales during the year. Its exits included those from retail unicorn Lenskart, SaaS Startup Pixis and baby pr

Blackstone, MO Alts and InvAscent win APEX'24 Private Equity Awards

Press Release Blackstone, MO Alternates (formerly Motilal Oswal PE) and InvAscent were awarded as among the leading Private Equity and Growth Capital investors in India for 2023 as part of Venture Intelligence APEX‘24 Private Equity & Venture Capital awards event in Mumbai.  The Venture Intelligence “Awards for Private Equity Excellence” (APEX) is dedicated to celebrating the best that the Indian Private Equity & Venture Capital industry has to offer. The APEX Awardees are selected based on both Self Nomination by the participating PE-VC firms and "crowd sourced" voting from the Limited Partner, PE-VC and advisory communities. (The main criteria are Return Track Record, New Fund Raises & Follow-on Funding Rounds for Portfolio Companies) PE Investor of the Year Blackstone received the Private Equity Investor of the Year 2023 Award on the back of strong complete exits during the year: from Sona Comstar and IBS Software. Ganesh Mani and Amit Dalmia, Senior Managing D

Avendus tops League Table for Transaction Advisors to PE deals in Q1'23

Aeka Advisors and Ambit claim the No.2 & 3 slot Avendus topped the Venture Intelligence League Table for Transaction Advisor to Private Equity Transactions for Q1 2023 advising 5 deals worth $808 million. Aeka Advisors stood second having advised 3 deals worth $228 million. Ambit followed with 4 deals worth $160 million. Ernst & Young ($114 million across 4 deals) and o3 Capital ($80 million across 2 deals) completed the top five for Q1 2023. Avendus acted as advisor to ADIA’s $500 million investment in omnichannel eyewear retailer Lenskart . Aeka Advisors acted as advisor to Kreditbee’s $160 million fundraise from Advent International, Mitsubishi UFJ Financial Group (MUFG) and existing investors. Ambit advised the $104 million fundraise of Freshtohome from Mount Judi Ventures, Iron Pillar, Amazon and others. The  Venture Intelligence League Tables , the first such initiative exclusively tracking transactions involving India-based companies, are based on the value of PE

PE-VC investments fall 38% in 2023 to below $30 B

The value of investments by Private Equity - Venture Capital (PE-VC) firms in India fell by 38% to less than $30 Billion in 2023. PE-VC firms invested $29.7 Billion (across 756 deals) in Indian companies in 2023, compared to $47.6 Billion (across 1,362 deals) in the previous year, reports Venture Intelligenc e, a research service focused on private company financials, transactions, and their valuations. (Note: These figures exclude PE investments in Real Estate).                                                                                                                                                                      2023 witnessed 67 mega deals ($100 M+ rounds) worth $21.2 Billion, compared to 112 such investments worth $31.8 Billion in 2022. The $2.4 Billion investment in Manipal Hospitals by Temasek (which gained majority control) and TPG Capital was the largest PE-VC investment in 2023. This was followed by the $1.35 Billion buyout of education loans focused HDFC Credila